Bénédicte Stengel1, Christian Combe2, Christian Jacquelinet3, Serge Briançon4, Denis Fouque5, Maurice Laville5, Luc Frimat6, Christophe Pascal7, Yves-Édouard Herpe8, Pascal Morel9, Jean-François Deleuze10, Joost P Schanstra11, Ron L Pisoni12, Bruce M Robinson12, Ziad A Massy13. 1. Inserm U1018, centre de recherche en épidémiologie et santé des populations (CESP), 16, avenue Paul-Vaillant-Couturier, 94807 Villejuif cedex, France; UMR1018, université Paris Saclay, 16, avenue Paul-Vaillant-Couturier, 94807 Villejuif cedex, France; Université Paris-Sud, 16, avenue Paul-Vaillant-Couturier, 94807 Villejuif cedex, France; Université Versailles-Saint-Quentin, 55, avenue de Paris, 78000 Versailles, France. Electronic address: benedicte.stengel@inserm.fr. 2. Service de néphrologie transplantation dialyse, hôpital Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France; Inserm, U1026, 146, rue Léo-Saignat, 33076 Bordeaux cedex, France; Université Bordeaux Segalen, 146, rue Léo-Saignat, 33076 Bordeaux cedex, France. 3. Agence de la biomédecine, 1, avenue du Stade-de-France, 93210 Saint-Denis, France. 4. Inserm CIC-EC, CHU de Nancy Brabois, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France; Épidémiologie clinique, CHU de Nancy, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France. 5. Service de néphrologie, hôpital Lyon-Sud, hospices civils de Lyon, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université Claude-Bernard Lyon 1, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Inserm U1060, laboratoire CarMeN, CENS, BP 12, 69600 Oullins, France. 6. Inserm CIC-EC, CHU de Nancy Brabois, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France; Épidémiologie clinique, CHU de Nancy, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France; Service de néphrologie, CHU de Nancy Brabois, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France. 7. Université Lyon III Jean-Moulin, institut de formation et de recherche sur les organisations sanitaires et sociales, 18, rue Chevreul, 69007 Lyon, France. 8. Biobanque de Picardie, CHU d'Amiens Sud D408, 80000 Amiens, France; Centre hospitalier universitaire, D408, 80000 Amiens, France. 9. Établissement français du sang Bourgogne-Franche-Comté, UMR 1098, 8, rue du Docteur-Jean-François-Xavier-Girod, 25000 Besançon, France. 10. Centre national de génotypage, CEA, 2, rue Gaston-Crémieux, CP 5721, 91057 Évry cedex, France. 11. Inserm U1048, institut des maladies métaboliques et cardiovasculaires, 1, avenue Jean-Poulhès, BP 84225, 31432 Toulouse cedex 4, France; Université Toulouse III Paul-Sabatier, 1, avenue Jean-Poulhès, BP 84225, 31432 Toulouse cedex 4, France. 12. Arbor Research Collaborative for Health, 40 E Huron St, suite 300, Ann Arbor, MI 48104, États-Unis. 13. Inserm U1018, centre de recherche en épidémiologie et santé des populations (CESP), 16, avenue Paul-Vaillant-Couturier, 94807 Villejuif cedex, France; UMR1018, université Paris Saclay, 16, avenue Paul-Vaillant-Couturier, 94807 Villejuif cedex, France; Université Versailles-Saint-Quentin, 55, avenue de Paris, 78000 Versailles, France; Service de néphrologie, hôpital Ambroise-Paré, AP-HP, 9, avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France.
Abstract
BACKGROUND: Preserving kidney function and improving the transition from chronic kidney disease to end stage is a research and healthcare challenge. The national Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort was established to identify the determinants, biomarkers and practice patterns associated with chronic kidney disease outcomes. METHODS: The study will include more than 3000 adult patients with moderate to advanced chronic kidney disease from a representative sample of 40 nephrology clinics with respect to regions and legal status, public or private. Patients are recruited during a routine visit and followed for 5 years, before and after starting renal replacement therapy. Patient-level clinical, biological, and lifestyle data are collected annually, as well as provider-level data on clinical practices, coordinated with the International Chronic Kidney Disease Outcomes and Practice Pattern Study. Blood and urine samples are stored in a biobank. Major studied outcomes include survival, patient-reported outcomes, disease progression and hospitalizations. RESULTS: More than 13,000 eligible patients with chronic kidney disease were identified, 60% with stage 3 and 40% with stage 4. Their median age is 72 years [interquartile range, 62-80 years], 60% are men and 38% have diabetes. By the end of December 2015, 2885 patients were included. CONCLUSION: The CKD-REIN cohort will serve to improve our understanding of chronic kidney disease and provide evidence to improve patient survival and quality of life as well as health care system performances.
BACKGROUND: Preserving kidney function and improving the transition from chronic kidney disease to end stage is a research and healthcare challenge. The national Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort was established to identify the determinants, biomarkers and practice patterns associated with chronic kidney disease outcomes. METHODS: The study will include more than 3000 adult patients with moderate to advanced chronic kidney disease from a representative sample of 40 nephrology clinics with respect to regions and legal status, public or private. Patients are recruited during a routine visit and followed for 5 years, before and after starting renal replacement therapy. Patient-level clinical, biological, and lifestyle data are collected annually, as well as provider-level data on clinical practices, coordinated with the International Chronic Kidney Disease Outcomes and Practice Pattern Study. Blood and urine samples are stored in a biobank. Major studied outcomes include survival, patient-reported outcomes, disease progression and hospitalizations. RESULTS: More than 13,000 eligible patients with chronic kidney disease were identified, 60% with stage 3 and 40% with stage 4. Their median age is 72 years [interquartile range, 62-80 years], 60% are men and 38% have diabetes. By the end of December 2015, 2885 patients were included. CONCLUSION: The CKD-REIN cohort will serve to improve our understanding of chronic kidney disease and provide evidence to improve patient survival and quality of life as well as health care system performances.
Authors: Aurélie Affret; Douae El Fatouhi; Courtney Dow; Emmanuelle Correia; Marie-Christine Boutron-Ruault; Guy Fagherazzi Journal: J Med Internet Res Date: 2018-07-05 Impact factor: 5.428